Boston, June 15, 2026 /PRNewswire/ — Biocytogen (HKEX: 02315; SSE: 688796) today announced that its Boston R&D Center has officially received AAALAC International accreditation. AAALAC International is a globally recognized authoritative certification body in the field of laboratory animal care and use, dedicated to promoting continuous improvement in laboratory animal management and research quality.
This accreditation underscores Biocytogen’s long-standing commitment to high standards of animal welfare, scientific rigor, and excellence in operational systems, further solidifying the company’s foundation for high-quality development in preclinical research and innovative drug discovery.
Biocytogen’s Boston R&D Center is a key component of the company’s global drug discovery and translational research layout, providing critical support for its expanding innovative drug R&D business. Leveraging advanced research facilities and a professional team, the center can conduct a variety of in vivo studies covering monoclonal antibodies, multispecific antibodies, antibody-drug conjugates (ADCs), cell therapies, and other innovative biologics, offering high-quality R&D services to global pharmaceutical and biotechnology partners.
Relying on its proprietary BioMice® platform, Biocytogen has established an industry-leading resource library of genetically engineered disease models, covering multiple therapeutic areas including oncology, immunology and autoimmune diseases, metabolic diseases, neuroscience, and ophthalmic diseases. Combined with the company’s RenMice® fully human antibody discovery platform and AI-powered antibody discovery technology system, Biocytogen can provide global partners with end-to-end support from target validation and candidate drug discovery to preclinical development, accelerating the development of innovative therapies.
Madeline Lee, Chief Operating Officer (COO) of Biocytogen, stated: “Obtaining AAALAC International accreditation is a significant milestone for Biocytogen’s Boston R&D Center, further demonstrating our unwavering commitment to high standards of research quality, animal welfare, and standardized research management. As our global collaboration network continues to expand, this accreditation will further enhance partners’ confidence in our research quality, animal care standards, and scientific rigor. Leveraging our industry-leading disease model resources and antibody discovery platforms, we will continue to empower global partners, accelerate innovative drug development, and bring more breakthrough treatment options to patients worldwide.”
AAALAC International accreditation is widely regarded as the “gold standard” in laboratory animal care and use. Institutions that achieve this certification not only meet regulatory requirements but also continuously uphold high standards of animal welfare, research ethics, and research quality, while driving ongoing optimization of related systems.
This AAALAC International accreditation further strengthens Biocytogen’s ability to serve global pharmaceutical and biotechnology companies. By providing high-quality translational research, in vivo pharmacodynamic evaluations, and innovative drug discovery solutions, while consistently adhering to the principle of balancing animal welfare with scientific rigor, Biocytogen is committed to helping partners obtain more reliable preclinical research data, reduce R&D risks, and accelerate the development of innovative therapies in areas such as oncology, immunology and autoimmune diseases, metabolic diseases, neuroscience, and ophthalmic diseases.
About Biocytogen
Biocytogen (Stock Codes: 688796.SH; 02315.HK) is an innovative technology-driven international biotechnology company focused on new drug R&D, committed to becoming a global source of new drugs. Centered on its proprietary gene editing technology, the company has built a dual-engine platform combining a “fully human antibody molecule library” and a “target-humanized mouse library,” systematically accelerating global drug development. Biocytogen has independently developed the RenMice® fully human antibody platform (including RenMab®, RenLite®, RenNano®, RenTCR™, RenTCR mimic™) for the discovery of therapeutic fully human monoclonal antibodies, bispecific/multispecific antibodies, bispecific ADCs, nanobodies, and TCR-like antibodies. Focusing on over 1,000 potentially druggable targets, the company is advancing a large-scale antibody discovery initiative—”One Thousand Mice, Ten Thousand Antibodies™”—which has generated a library of over 1 million authentic fully human antibody sequences and is open for global collaboration. As of December 31, 2025, Biocytogen has signed over 350 drug collaboration, licensing, or transfer agreements. The company’s sub-brand, BioMice, has established thousands of genetically engineered animal/cell models, possesses the world’s largest collection of target-humanized mouse models, and provides global clients with full-chain support including preclinical pharmacology and efficacy studies, gene editing services, and model construction. Biocytogen is headquartered in Beijing, with branches in China (Haimen, Jiangsu; Shanghai), the United States (Boston, San Francisco, San Diego), and Heidelberg, Germany, forming a global R&D and operations network. For more information, please visit the official website: https://biocytogen.com.cn/